On World Diabetes Day, Sanofi is celebrating an approval recommendation in the EU for Teizeild, a first-in-class drug designed to delay the progression of type 1 diabetes (T1D). The EMA's human ...
Novo Nordisk has jumped the gun on US price reductions for its blockbuster diabetes and weight-loss drug semaglutide, cutting the monthly price to $349, earlier than expected, for people willing to ...
Bristol Myers Squibb and Johnson & Johnson have said they will stop development of their oral Factor XIa inhibitor milvexian in acute coronary syndrome after a disappointing trial result. The decision ...
A phase 2 trial of enGene's detalimogene voraplasmid in non-muscle invasive bladder cancer (NMIBC) has delivered a positive result, setting it on course for a filing with the FDA next year. The LEGEND ...
A report has suggested the UK is seeing an exodus of skilled science, technology, engineering, and mathematics (STEM) workers to other countries, placing the country's economic future at risk. The ...
Both these factors can be tied in part to J&J’s strong presence in the consumer sector – but behind household name products is a strong pharmaceutical backbone that has emerged over the company’s long ...
People with hypertension were twice as likely to take their medicine regularly when offered cash incentives, but that did not translate into improved blood pressure control. The curious finding was ...
CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...
Now in its 7th year, our free-to-attend careers event will be held at the Royal Society of Medicine on the 18th February 2026 ...
At ESMO 2025, pharmaphorum spoke with Dr Ebrahim Delpassand, CEO of RadioMedix, an emerging, clinical-stage biotech company ...
The direct-to-employer (DTE) is an industry first for FDA-approved weight-loss drugs like Novo Nordisk's Wegovy (semaglutide) ...
Leela Barham highlights data that shows that indication-specific pricing has been used in England for at least four years and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback